by Peter Ciszewski | Sep 26, 2017
X4 Pharmaceuticals, a clinical stage biotechnology company developing a novel CXCR4 inhibitor drug to improve immune cell trafficking to treat cancer and rare diseases, today announced Phase 1 results from the company’s ongoing Phase 1/2 study of X4P-001-IO. The data...
by Peter Ciszewski | Sep 26, 2017
The American Academy of Pediatrics (AAP) welcomes efforts in the U.S. House of Representatives to reauthorize the Maternal, Infant, and Early Childhood Home Visitation (MIECHV) program during today’s consideration of a bill, the Increasing Opportunity through...
by Peter Ciszewski | Sep 25, 2017
Patients with multiple myeloma regularly receive bisphosphonates to protect their bones against lytic lesions, but a new study suggests that the novel agent denosumab could be used instead. In a head-to-head comparison with zoledronic acid in a trial involving more...
by Peter Ciszewski | Sep 25, 2017
Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals discusses treatment options for acute myelogenous leukemia (AML), which comprise a variety of chemotherapy regimens and stem cell transplantation. Current standard chemotherapy regimens cure only a minority...
by Peter Ciszewski | Sep 25, 2017
Survival outcomes in chronic myeloid leukemia (CML) treated with imatinib as monotherapy are high and are not necessarily influenced by faster responses or disease-related factors, with outcomes more associated with comorbidities and external factors, according to...
